BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 31659068)

  • 1. Europium Nanoparticle-Based Sialyl-Tn Monoclonal Antibody Discriminates Epithelial Ovarian Cancer-Associated CA125 from Benign Sources.
    Gidwani K; Nadeem N; Huhtinen K; Kekki H; Heinosalo T; Hynninen J; Perheentupa A; Poutanen M; Carpen O; Pettersson K; Lamminmäki U
    J Appl Lab Med; 2019 Nov; 4(3):299-310. PubMed ID: 31659068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources.
    Gidwani K; Huhtinen K; Kekki H; van Vliet S; Hynninen J; Koivuviita N; Perheentupa A; Poutanen M; Auranen A; Grenman S; Lamminmäki U; Carpen O; van Kooyk Y; Pettersson K
    Clin Chem; 2016 Oct; 62(10):1390-400. PubMed ID: 27540033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploratory Analysis of CA125-MGL and -STn Glycoforms in the Differential Diagnostics of Pelvic Masses.
    Salminen L; Nadeem N; Rolfsen AL; Dørum A; Laajala TD; Grènman S; Hietanen S; Heinosalo T; Perheentupa A; Poutanen M; Bolstad N; Carpén O; Lamminmäki U; Pettersson K; Gidwani K; Hynninen J; Huhtinen K
    J Appl Lab Med; 2020 Mar; 5(2):263-272. PubMed ID: 32445385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Difference in mesothelin-binding ability of serum CA125 between patients with endometriosis and epithelial ovarian cancer.
    Sasaki A; Akita K; Ito F; Mori T; Kitawaki J; Nakada H
    Int J Cancer; 2015 Apr; 136(8):1985-90. PubMed ID: 25197000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different levels of sialyl-Tn antigen expressed on MUC16 in patients with endometriosis and ovarian cancer.
    Akita K; Yoshida S; Ikehara Y; Shirakawa S; Toda M; Inoue M; Kitawaki J; Nakanishi H; Narimatsu H; Nakada H
    Int J Gynecol Cancer; 2012 May; 22(4):531-8. PubMed ID: 22367369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant glycosylation of α3 integrins as diagnostic markers in epithelial ovarian cancer.
    Jain S; Parimelazhagan Santhi P; Vinod R; Afrin Ruma S; Huhtinen K; Pettersson K; Sundfeldt K; Leivo J; Gidwani K
    Clin Chim Acta; 2023 Mar; 543():117323. PubMed ID: 37003518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spectrally separated dual-label upconversion luminescence lateral flow assay for cancer-specific STn-glycosylation in CA125 and CA15-3.
    Ekman M; Salminen T; Raiko K; Soukka T; Gidwani K; Martiskainen I
    Anal Bioanal Chem; 2024 May; 416(13):3251-3260. PubMed ID: 38584178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
    Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
    Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease.
    Zheng H; Gao Y
    Int J Gynecol Cancer; 2012 Jul; 22(6):1000-5. PubMed ID: 22426406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The performance of Carbohydrate Antigen 125-Thomsen-nouveau and anti-Müllerian hormone combined with CA125, Human epididymis protein 4 and Risk of Malignancy Algorithm in diagnosis for patients with Epithelial ovarian cancer.
    Hou X; Liu S; Liu J; Zhou J; Liang Y; Cui L
    Clin Biochem; 2023 Sep; 119():110615. PubMed ID: 37517433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical value of the combined detection of sEGFR, CA125 and HE4 for epithelial ovarian cancer diagnosis.
    Li Y; Wang ZC; Luo L; Mu CY; Xu J; Feng Q; Li SB; Gu B; Ma P; Lan T
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):604-610. PubMed ID: 32016961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic value of serum D-dimer, CA125, and neutrophil-to-lymphocyte ratio in differentiating ovarian cancer and endometriosis.
    Chen L; Wang X; Shu J; Xu S; Wu Q; Yu Y
    Int J Gynaecol Obstet; 2019 Nov; 147(2):212-218. PubMed ID: 31469423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of plasma amino acid profile-based index and CA125 in the diagnosis of epithelial ovarian cancers and borderline malignant tumors.
    Miyagi E; Maruyama Y; Mogami T; Numazaki R; Ikeda A; Yamamoto H; Hirahara F
    Int J Clin Oncol; 2017 Feb; 22(1):118-125. PubMed ID: 27623814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycovariant-based lateral flow immunoassay to detect ovarian cancer-associated serum CA125.
    Bayoumy S; Hyytiä H; Leivo J; Talha SM; Huhtinen K; Poutanen M; Hynninen J; Perheentupa A; Lamminmäki U; Gidwani K; Pettersson K
    Commun Biol; 2020 Aug; 3(1):460. PubMed ID: 32826955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
    Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
    Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis.
    Bandiera E; Zanotti L; Fabricio AS; Bucca E; Squarcina E; Romani C; Tassi R; Bignotti E; Todeschini P; Tognon G; Romagnolo C; Gion M; Sartori E; Maggino T; Pecorelli S; Ravaggi A
    Clin Chem Lab Med; 2013 Sep; 51(9):1815-24. PubMed ID: 24013103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the sensitivity and specificity of serum level of prostasin, CA125, LDH, AFP, and hCG+β in epithelial ovarian cancer patients.
    Bastani A; Asghary A; Heidari MH; Karimi-Busheri F
    Eur J Gynaecol Oncol; 2017; 38(3):418-424. PubMed ID: 29693884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the value of preoperative CYFRA21-1 in the diagnosis and prognosis of epithelial ovarian cancer in conjunction with CA125.
    Jin C; Yang M; Han X; Chu H; Zhang Y; Lu M; Wang Z; Xu X; Liu W; Wang F; Ju S
    J Ovarian Res; 2019 Nov; 12(1):114. PubMed ID: 31767040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical application of HE4 and CA125 in ovarian cancer type I and type II detection and differential diagnosis.
    Gąsiorowska E; Michalak M; Warchoł W; Lemańska A; Jasiński P; Spaczyński M; Nowak-Markwitz E
    Ginekol Pol; 2015 Feb; 86(2):88-93. PubMed ID: 25807831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the clinical significances of serum HE4 with CA125 in peritoneal tuberculosis and epithelial ovarian cancer.
    Zhang L; Chen Y; Liu W; Wang K
    Biomarkers; 2016; 21(2):168-72. PubMed ID: 26667154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.